Fasudil hydrochloride
Phase 2Small molecule
Fasudil hydrochloride is one of 49 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
207 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Afinitor
NovartisPhase 3
Neulasta
AmgenPhase 3
Taxotere
AAvyxa
Phase 3
Elahere
IImmunogenics, LLC
Phase 3
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vascular Function1 trial
Red Blood Cell ATP Release and Vascular Function in Humans
Completed·—·Phase 2·NCT03404843·31 enrolled
Atherosclerosis1 trial
Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis
Terminated·—·Phase 2·NCT00670202·2 enrolled
Ovarian Cancer1 trial
Myocardial Infarction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fasudil hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTechnical University of Munich